ASHLEY WOZNIAK: Open Payments
NPI 1770006637 · LIVONIA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 34 payments from 13 companies in 2025. Trend: 2023 $9,185 · 2024 $807 · 2025 $822
Food & beverage: $806Education: $16
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $182 |
| Novartis Pharmaceuticals Corporation | 4 | $155 |
| Travere Therapeutics, Inc. | 6 | $91 |
| Ardelyx, Inc. | 3 | $68 |
| Vifor Pharma, Inc. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $62 |
| Calliditas Therapeutics US Inc. | 2 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Alexion Pharmaceuticals, Inc. | 1 | $29 |
| AKEBIA THERAPEUTICS INC | 1 | $22 |
Products named: Kerendia, Vanrafia, IBSRELA, Veltassa, TARPEYO, JARDIANCE, VOYXACT, ULTOMIRIS.
Industry payments across MI — which companies pay providers there.
